Please login to the form below
testosterone
This page shows the latest testosterone news and features for those working in and with pharma, biotech and healthcare.
FDA approves Myovant’s oral pill Orgovyx for prostate cancer
In this study, Orgovyx achieved sustained testosterone suppression to castrate levels in 96.7% of patients from week five to week 48, in comparison to 88.8% for those receiving leuprolide ... It is designed to block the GnRH receptor, which in return
Latest news
-
Myovant preps US filing for relugolix in prostate cancer
A response in the trial was defined as achieving and maintaining testosterone suppression at castration levels over the course of the 48-week study, and relugolix cleared the 90% rate required ... The data also showed that relugolix was also more
-
Bayer preps filings for new prostate cancer drug
The new drug has a fairly benign safety profile, which is put down to the fact that it has minimal blood-brain barrier penetration and does not significantly increase testosterone levels
-
Bayer picks up PMEA award for multi-channel engagement
London. The work, delivered with support from digital agency Oi, provided a novel approach to restoring growth to Bayer’s established testosterone market leader Nebido.
-
Astellas’ Xtandi cancer drug rejected by NICE
cancer who have already had treatment to reduce testosterone and have had docetaxel chemotherapy. .
-
Transition takes on Lilly muscle-boosting drug
Despite its effect on testosterone levels there was no accompanying increase in prostate specific antigen (PSA) levels. ... PSA levels are known to rise with testosterone replacement therapy (TRT) and there have been concerns TRT could activate or
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
Clarus Therapeutics pushed through with the launch of its testosterone replacement tablet, Jatenzo, despite the disruption caused by COVID-19.
-
Case study: Tackle TD for Bayer UK
Client:Bayer UK. Agency:Virgo Health and Oi Ltd. Campaign:Tackle TD. Timescale:N/A. Testosterone deficiency affects around one million British men, but symptoms like fatigue are often ignored, and ... One million British men are estimated to have
-
Deal Watch April 2016
50 . Acerus (CA). Aytu (US). US license and commercialisation. Approved nasal testosterone for treatment of hypogonadism.
-
Deal Watch table for October 2014
130. TesoRx Pharma/Aspen. Licence [C]. For TSX 002 an unmodified oral testosterone replacement.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Antares appoints David Bergstrom as SVP
The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.
-
Former Pfizer VP joins Antares
methotrexate) for arthritis and advance the development of testosterone replacement therapy Vibex QS T.
-
Galectin Therapuetics appoints Harold Shlevin as chief operating officer
Previously, he served as president and CEO of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US and he was co-founder
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Management
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Account Manager
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- GSK’s revenue drops by 18% in Q1 as performance pressures mount
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
- Live Webinar: Blockchain in Healthcare: Predictions for the Post-COVID World
- Live Webinar: Digital Health for Improving Care in Disadvantaged Populations
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Illingworth Research Group wins ‘prestigious’ Queen’s Award
- Working in true partnership in a time of change
- Live Webinar: The Future of Digital Pills
- Total COVID-19 vaccine spending to reach $157bn by 2025, says report
- NICE sets out plans for ‘ambitious’ five-year strategy
- Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
- PMEA 2021 has officially launched – with a new online entry system
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
